Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 09 2020 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Richard Murray, Ph.D., chief executive officer and president of
Jounce Therapeutics, will present at the 38th Annual J.P. Morgan
Healthcare Conference on Thursday, January 16, 2020 at 8:00 AM PT
(11:00 AM ET) in San Francisco. Following the presentation,
management will participate in a question and answer session at
8:30 AM PT (11:30 AM ET).
A live webcast of the presentation will be available by visiting
“Events and Presentations” in the Investors and Media section of
Jounce’s website at www.jouncetx.com. A replay of the webcast will
be archived for 30 days following the presentation.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Through
the use of its Translational Science Platform, Jounce first focuses
on specific cell types within the human tumor microenvironment to
prioritize targets, and then identifies related biomarkers designed
to match the right immunotherapy to the right patient. Jounce is
developing two clinical-stage programs, vopratelimab, a monoclonal
antibody that binds to and activates ICOS, and JTX-4014, a PD-1
inhibitor intended for potential combination use with Jounce’s
broader pipeline. Vopratelimab is currently being assessed in a
Phase 2 clinical trial and JTX-4014 Phase 1 data were reported in
November 2019 with additional studies planned. Jounce is also
advancing and building out its broad and wholly-owned discovery
pipeline of immuno-oncology targets, including those expressed on
T-regulatory cells, macrophages and stromal cells. In addition,
Jounce has exclusively licensed worldwide rights to JTX-8064, a
LILRB2 receptor antagonist, to Celgene, a wholly owned subsidiary
of Bristol-Myers Squibb Company. For more information, please visit
www.jouncetx.com.
Investor and Media Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024